Bolt Biotherapeutics to Acquire Prana Therapies, Raises $120 Million in Private Placement
Bolt announced the acquisition of Prana Therapies and a concurrent $120 million private placement to advance PRA-216 in inflammatory indications.
Story updates
01:14:20 PM UTC
SquawkNews
Bolt acquired Prana in a reverse merger and entered a $120M private placement, with up to $60M more via warrants. Pro forma, prior Bolt holders own ~6.9% fully diluted; cash runway expected into 2028.Material DetailsContext by AI AnalystThis is a strategic pivot via reverse merger, refocusing Bolt…
01:19:55 PM UTC
SquawkNews
Bolt Biotherapeutics: Acquisition Was Structured as a Sign-And-Close Reverse Merger >BOLT
REDWOOD CITY, Calif., Oct. 23, 2026 (GLOBE NEWSWIRE) — Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) (“Bolt” or the “Company”) announced today that it is acquiring Prana Therapies, Inc. (“Prana”), a clinical-stage biotechnology company developing next-generation half-life-extended multispecific antibodies…